BACKGROUND OF THE DISCLOSURE
The field of the disclosure relates generally to a potent and specific oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor and to methods of administering the inhibitor for treating autoimmune diseases, and in particular, to
BACKGROUND OF THE DISCLOSURE
The field of the disclosure relates generally to a potent and specific oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor and to methods of administering the inhibitor for treating autoimmune diseases, and in particular, to
The present invention relates to a new use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula I in which the symbols and substituents have the meaning as given hereinafter in free form or in pharmaceutically acceptable salt form, said
The present invention relates to new derivatives of trypsin-kallikrein inhibitor, obtainable from cattle organs, which is called BPTI (basic pancreatic trypsin inhibitor [Kunitz]) in the text which follows, and to processes for the preparation of these derivatives from natural BPTI or from
اكتب أحد الأعراض أو المرض واقرأ عن الأعشاب التي قد تساعد ، واكتب عشبًا واطلع على الأمراض والأعراض التي تستخدم ضدها. * تستند جميع المعلومات إلى البحوث العلمية المنشورة